The progression of Parkinson disease
A hypothesis
Abstract
Recent neuropathologic studies suggest that Parkinson disease (PD) does not begin in the substantia nigra compacta (SNc) but only involves this region later in the course of the disease. It is proposed that once the SNc is affected by the original pathobiological process (for example, protein aggregation), additional processes more specific to dopaminergic neurons are triggered (including sources of oxidative stress such as increased dopamine turnover, reduced levels of reduced glutathione, increased iron, and the presence of neuromelanin, as well as altered calcium homeostasis and excitotoxicity). This results in an acceleration of cell loss in the SNc, causing nigrostriatal degeneration to both reach a threshold for symptoms in advance of earlier affected brain areas and progress more rapidly than other aspects of the disease. Neuroprotective therapy directed solely at more general biologic processes may not have sufficient effects on this accelerated degeneration in the SNc, while neuroprotective therapy designed exclusively to slow the progression of dopaminergic cell loss will not alter the progression of the nondopaminergic symptoms that contribute the greatest disability in the later stages of the disease. Effective disease-modifying therapy may require a cocktail combining treatments designed to address the basic mechanisms of the neurodegeneration and the additional biologic processes specific to the dopaminergic SNc. This hypothesis has implications for the development of disease-modifying therapy and the interpretation of endpoints of clinical trials evaluating the efficacy of such treatments.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449–458.
2.
Lang AE, Obeso JA. Current challenges in Parkinson's disease: restoring the nigrostriatal dopamine system will not suffice. Lancet Neurol 2004;3:309–316.
3.
Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190–199.
4.
Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004;55:761–765.
5.
Braak H, Del Tredici K, Rüb U, De Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211.
6.
Del Tredici K, Rüb U, De Vos RAI, Bohl JRE, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413–426.
7.
Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003;60:601–605.
8.
Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001;16:41–46.
9.
Ponsen MM, Stoffers D, Booij J, Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173–181.
10.
Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456–462.
11.
Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331–339.
12.
Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005;65:1442–1446.
13.
Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000;41:71–77.
14.
Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 2003;62:363–367.
15.
Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998;51:2–9.
16.
Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876–880.
17.
Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57–87.
18.
Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann NY Acad Sci 2000;899:112–120.
19.
Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53:S26–S36.
20.
McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003;179:38–46.
21.
Hirsch EC, Mouatt A, Thomasset M, Javoy-Agid F, Agid YA, Graybiel AM. Expression of calbindin D28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution in Parkinson's disease. Neurodegeneration 1992;1:83–93.
22.
Van den MP, Luk KC, Ste-Marie L, et al. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 2003;130:2535–2542.
23.
Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998;44:S115–120.
24.
Teismann P, Tieu K, Cohen O, et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003;18:121–129.
25.
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364–1371.
26.
Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003;184:S68–S79.
27.
Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006;66:845–851.
28.
Paisan-Ruiz C, Lang AE, Kawarai T, et al. LRRK2 gene in Parkinson disease—mutation analysis and case control association study. Neurology 2005;65:696–700.
Information & Authors
Information
Published In
Copyright
© 2007.
Publication History
Published online: March 19, 2007
Published in print: March 20, 2007
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Functional activity, functional connectivity and complex network biomarkers of progressive hyposmia Parkinson’s disease with no cognitive impairment: evidences from resting-state fMRI study, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1455020
- Research Priorities on the Role of α‐ Synuclein in Parkinson's Disease Pathogenesis , Movement Disorders, (2024).https://doi.org/10.1002/mds.29897
- Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach, Expert Review of Neurotherapeutics, 23, 1, (15-24), (2023).https://doi.org/10.1080/14737175.2023.2176220
- Targeting α‐Synuclein : A Further Viewpoint , Movement Disorders, 38, 4, (715-716), (2023).https://doi.org/10.1002/mds.29345
- Synthesis, in silico prediction of sites of metabolism and in-vitro hepatotoxicity evaluationofnew seriesN’-substituted 3-(1,3,7-trimethyl-xanthin-8-ylthio)propanehydrazides, Pharmacia, 69, 2, (351-361), (2022).https://doi.org/10.3897/pharmacia.69.e83535
- Effects of Alcohol Consumption on Oxidative Stress in a Sample of Patients Recruited in a Dietary Center in a Southern University Hospital: A Retrospective Study, Medicina, 58, 11, (1670), (2022).https://doi.org/10.3390/medicina58111670
- Androgens and Parkinson’s disease: the role in humans and in experiment, Problems of Endocrinology, 68, 6, (146-156), (2022).https://doi.org/10.14341/probl13148
- Androgens and Parkinson's Disease: A Review of Human Studies and Animal Models, Androgens: Clinical Research and Therapeutics, 2, 1, (294-303), (2021).https://doi.org/10.1089/andro.2021.0011
- Anatomical and neurochemical organization of the serotonergic system in the mammalian brain and in particular the involvement of the dorsal raphe nucleus in relation to neurological diseases, 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part B, (41-81), (2021).https://doi.org/10.1016/bs.pbr.2021.02.003
- Parkinsonism, Principles and Practice of Movement Disorders, (82-120.e21), (2021).https://doi.org/10.1016/B978-0-323-31071-0.00004-4
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.
Lang's Medical Hypothesis article on progression of Parkinson's disease (PD) [1] inverts the Braak hypothesis. [2] Lang notes that Braak based his hypothesis on Lewy bodies (LB) in brainstem neurons and not on neuronal counts. Lang also suggests that loss of non dopamine (DA) neurons occurs after loss of substantia nigra (SN) DA neurons and not before. He predicts that non motor symptoms (e.g. depression, sleep and autonomic disturbances) due to loss of non DA neurons will persist after a neuroprotective treatment for DA neurons. Consequently, Lang suggests the need for a complex therapeutic cocktail to address basic neurodegenerative mechanisms in DA and non DA neurons alike. However, almost all non DA neuron loss in PD occurs in catecholamine (CA) neurons such as norepinephrine (NE) neurons in locus ceruleus and dorsal motor nucleus of the vagus, epinephrine (Epi) neurons in the rostral ventral lateral medulla and in serotonin (5HT) neurons in the dorsal raphe. [3] Loss of these non DA aminergic neurons can explain most of the major non motor symptoms in PD.
In addition, Blashko predicted that aldehyde MAO metabolites would be highly reactive and toxic to cells in which they are formed. [4] We confirmed Blashko's hypothesis showing that the MAO metabolites of DA, 3,4-dihydroxyphenylacetaldehyde (DOPAL) and of NE or Epi, 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL), are toxic at physiological levels in vitro and in vivo. [3] Both DOPAL and DOPEGAL form free radicals which activate the mitochondrial permeability transition pore leading to cell death. [3] In addition, DOPAL like other free radicals triggers aggregation of alpha-synuclein (AS) to form toxic oligomers and large LB-like(AS) aggregates. [3,5] Therefore these amine- derived aldehydes and their interaction with AS provide a simple explanation for PD pathology including selective amine (DA, NE, Epi, 5HT) neuron loss and large LB-like AS aggregates in the remaining neurons.
The difference in severity and progression of motor vs non motor symptoms in PD could be due to differences in toxicity of the specific amine-derived aldehyde as well as to differences in neuroprotective factors in subsets of aminergic neurons. For instance, we showed that DOPAL is more toxic to DA SN neurons than to DA ventral tegmental area neurons. [3]
Because PD selectively affects aminergic neurons which produce MAO aldehyde metabolites which have similar mechanisms of toxicity [3] there may be simpler neuroprotective treatment strategies,than Lang suggests [1] for most of the disabling motor and non motor PD symptoms.
References
1. Lang AE. The progression of Parkinson's disease. Neurology 2007; 68: 948-952.
2. Braak H, Del Tredici K, Rib U, De Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
3. Burke WJ, Li SW, Kumar VB, Kristal BS, Johnson EM, Ruggiero DA. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. NeuroToxicology 2004; 25: 101-115.
4. Blashko H. Amine oxidase and amine metabolism. Pharmacol Rev 1952; 4: 415-453.
5. Burke WJ, Kumar VB, Pan Y, Panneton WM, Pandey N, Galvin JE. DOPAL, the toxic dopamine metabolite, triggers alpha-synuclein aggregation in vivo. Neurology 2006; 65A.
Disclosure: The author reports no conflicts of interest.
I thank Dr. Burke for his interest in my hypothesis article. My main proposal is that nigral dopaminergic cell loss may be accelerated for various reasons which could include the mechanisms outlined in his letter. His work is not incompatible with my hypothesis and may correspond to it by adding similar but less pronounced "accelerated" degeneration in other catecholaminergic neurons. Just as the VTA may be less sensitive than SNc neurons to these factors -- as Dr. Burke points out --so may NE, Epi and 5HT neurons (still allowing for a greater acceleration of the degenerative process of the nigra).
However, I did not suggest "that loss of non-dopamine neurons occurs after loss of substantia nigra dopamine neurons not before". It is also important to point out that, in contrast to Dr. Burke's claims, many regions of the CNS degenerate in PD and a number of these cannot be explained by a common catecholamine phenotype. As I outlined, there are many potential explanations for the non-dopaminergic, non-motor symptoms of PD. Unfortunately, there is no clear clinical-pathological understanding of these and although some may be explained by the loss of non-DA catecholaminergic neurons, many may not.
I am uncertain of the basis of Dr. Burke's strong statement that "Loss of these non-DA aminergic neurons can explain most of the major nonmotor symptoms in PD". One critical example of this is dementia which may be partially explained by involvement of areas such as the cholinergic nucleus basalis of Meynert, hippocampus and other regions of the cortex (Table 1). [1]
It would be reasonable to add to my discussion the possibility of neuroprotective treatment designed to address MAO aldehyde metabolites which, if Burke's hypothesis is correct, could theoretically influence dopaminergic and non-dopamine aminergic cell loss. However, this may still be inadequate to prevent progressive disability caused by the degenerative process involving other non-aminergic regions. Therefore, as proposed in my paper, the "cocktail" neuroprotective approach may still be required depending on when in the disease process treatment is initiated.
Disclosure: The author reports no conflicts of interest.